1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
246.73 USD   +0.48%
06/15Amgen Inc. Reaffirms Revenue Guidance for the Year 2022
CI
06/15TRANSCRIPT : Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 10:40 AM
CI
06/10Amgen announces webcast of goldman sachs 43rd annual healthcare conference
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Transcript : Amgen Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 09:20 AM

05/11/2022 | 12:20pm EDT
Welcome to the second day of the Bank of America Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. And we are thrilled to have with us on stage, Amgen. And...


© S&P Capital IQ 2022
All news about AMGEN INC.
06/15Amgen Inc. Reaffirms Revenue Guidance for the Year 2022
CI
06/15TRANSCRIPT : Amgen Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference..
CI
06/10Amgen announces webcast of goldman sachs 43rd annual healthcare conference
PR
06/08BEHIND ONE BIOTECH'S WATER CONSERVAT : Saving Every Drop
PU
06/08TRANSCRIPT : Amgen Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-20..
CI
06/07Amgen - FDA APPROVES RIABNI (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN (RITUXIMAB), FOR ..
AQ
06/06NEW BPCIA COMPLAINT : Genentech Files Suit Against Tanvex Regarding Its Proposed Herceptin..
AQ
06/06Amgen Says FDA Approves Riabni to Treat Rheumatoid Arthritis
MT
06/06FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ..
PR
06/06Amgen Inc. Announces U.S. Food and Drug Administration Approves RIABNI
CI
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 214 M - -
Net income 2022 6 802 M - -
Net Debt 2022 26 905 M - -
P/E ratio 2022 19,4x
Yield 2022 3,09%
Capitalization 131 B 131 B -
EV / Sales 2022 6,03x
EV / Sales 2023 5,73x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 245,55 $
Average target price 246,51 $
Spread / Average Target 0,39%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.9.15%131 173
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782